NCT01232335
Completed
Not Applicable
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation for Long-term Use
ConditionsBronchial Asthma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bronchial Asthma
- Sponsor
- AstraZeneca
- Enrollment
- 1500
- Locations
- 1
- Primary Endpoint
- Incidence of Adverse Events
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this study is to confirm the safety profile for long term treatment and maximize doses and the control status on bronchial asthma in daily clinical usage
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients treated with Symbicort for the first time possibly at the higher dose due to bronchial asthma
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Incidence of Adverse Events
Time Frame: Range of one year
Secondary Outcomes
- The level of asthma control under long-term use(At the end of one year)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) PatientsChronic Obstructive Pulmonary DiseaseNCT01713075AstraZeneca1,183
Completed
Not Applicable
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever TherapyBronchial AsthmaNCT01711840AstraZeneca2,409
Completed
Not Applicable
Symbicort Turbuhaler 30/60 Clinical Experience InvestigationBronchial AsthmaNCT01232348AstraZeneca3,643
Completed
Phase 3
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mgAsthmaNCT00242775AstraZeneca2,100
Completed
Phase 3
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in JapanChronic Obstructive Pulmonary DiseaseNCT01070784AstraZeneca328